Prognostic nomogram combining
Humans
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
/ methods
Male
Female
Nomograms
Middle Aged
Lung Neoplasms
/ diagnostic imaging
Aged
Prognosis
Neoplasm Staging
ROC Curve
Adult
Kaplan-Meier Estimate
Proportional Hazards Models
Radiomics
18F-FDG PET/CT
Immunotherapy
Non-small cell lung cancer
Overall survive
Radiomics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 09 2024
04 09 2024
Historique:
received:
28
03
2024
accepted:
23
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
4
9
2024
Statut:
epublish
Résumé
The aim of this study was to establish and validate the precision of a novel radiomics approach that integrates 18Fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computed tomography (CT) scan data with clinical information to improve the prognostication of survival rates in patients diagnosed with stage III Non-Small Cell Lung Cancer (NSCLC) who are not candidates for surgery. We evaluated pretreatment
Identifiants
pubmed: 39231973
doi: 10.1038/s41598-024-71003-3
pii: 10.1038/s41598-024-71003-3
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20557Subventions
Organisme : Science and Technology Foundation of Xinjiang Uygur AutonomousRegion
ID : No.2022E02050
Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin. 71, 209 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Hirsch, F. R. et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 388, 1012 (2016).
doi: 10.1016/S0140-6736(16)31473-8
pubmed: 27598681
Bryan, S. et al. Cancer in Canada: Stage at diagnosis. Health Rep. 29, 21 (2018).
pubmed: 30566206
Auperin, A. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 2181 (2010).
doi: 10.1200/JCO.2009.26.2543
pubmed: 20351327
Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 1301 (2022).
doi: 10.1200/JCO.21.01308
pubmed: 35108059
pmcid: 9015199
Goldstraw, P. et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11, 39 (2016).
doi: 10.1016/j.jtho.2015.09.009
pubmed: 26762738
Ferreira-Junior, J. R. et al. CT-based radiomics for prediction of histologic subtype and metastatic disease in primary malignant lung neoplasms. Int J. Comput. Assist. Radiol. Surg. 15, 163 (2020).
doi: 10.1007/s11548-019-02093-y
pubmed: 31722085
Yang, F. et al. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy. Eur. Radiol. 32, 1538 (2022).
doi: 10.1007/s00330-021-08277-y
pubmed: 34564744
Li, J. et al. Evaluation of PD-L1 expression level in patients with non-small cell lung cancer by (18)F-FDG PET/CT radiomics and clinicopathological characteristics. Front. Oncol. 11, 789014 (2021).
doi: 10.3389/fonc.2021.789014
pubmed: 34976829
pmcid: 8716940
He, B. et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J. Immunother. Cancer 8, e000550 (2020).
doi: 10.1136/jitc-2020-000550
pubmed: 32636239
pmcid: 7342823
Kirienko, M. et al. FDG PET/CT as theranostic imaging in diagnosis of non-small cell lung cancer. Front. Biosci. 22, 1713 (2017).
doi: 10.2741/4567
Grootjans, W. et al. PET in the management of locally advanced and metastatic NSCLC. Nat. Rev. Clin. Oncol. 12, 395 (2015).
doi: 10.1038/nrclinonc.2015.75
pubmed: 25917254
Hatt, M. et al. 18F-FDG PET uptake characterization through texture analysis: Investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J. Nucl. Med. 56, 38 (2015).
doi: 10.2967/jnumed.114.144055
pubmed: 25500829
Chang, C. et al. A machine learning model based on PET/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma. Front. Oncol. 11, 603882 (2021).
doi: 10.3389/fonc.2021.603882
pubmed: 33738250
pmcid: 7962599
Shao, D. et al. Identification of stage IIIC/IV EGFR-mutated non-small cell lung cancer populations sensitive to targeted therapy based on a PET/CT radiomics risk model. Front. Oncol. 11, 721318 (2021).
doi: 10.3389/fonc.2021.721318
pubmed: 34796106
pmcid: 8593197
Yang, B. et al. Development and validation of a radiomics nomogram based on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and clinicopathological factors to predict the survival outcomes of patients with non-small cell lung cancer. Front. Oncol. 10, 1042 (2020).
doi: 10.3389/fonc.2020.01042
pubmed: 32766134
pmcid: 7379864
Huang, B. et al. Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT. Ebiomedicine 82, 104127 (2022).
doi: 10.1016/j.ebiom.2022.104127
pubmed: 35810561
pmcid: 9278031
Tibdewal, A. et al. Optimal standardized uptake value threshold for auto contouring of gross tumor volume using positron emission tomography/computed tomography in patients with operable nonsmall-cell lung cancer: Comparison with pathological tumor size. Indian J. Nucl. Med. 36, 7 (2021).
doi: 10.4103/ijnm.IJNM_134_20
pubmed: 34040289
pmcid: 8130683
Zhang, Y. et al. The utility of PET/CT metabolic parameters measured based on fixed percentage threshold of SUVmax and Adaptive iterative algorithm in the new revised FIGO staging system for stage III cervical cancer. Front Med. -Lausanne 8, 680072 (2021).
doi: 10.3389/fmed.2021.680072
pubmed: 34395472
pmcid: 8358139
Zwanenburg, A. et al. The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295, 328 (2020).
doi: 10.1148/radiol.2020191145
pubmed: 32154773
Zhao, T. et al. Radiotherapy prognosis-associated gene GCNT3 promotes the proliferation, migration and invasion of lung adenocarcinoma cells. Heliyon 8, e12100 (2022).
doi: 10.1016/j.heliyon.2022.e12100
pubmed: 36578381
pmcid: 9791338
Zhang, Y. H. et al. Development of a survival prognostic model for non-small cell lung cancer. Front. Oncol. 10, 362 (2020).
doi: 10.3389/fonc.2020.00362
pubmed: 32266143
pmcid: 7098984
Wang, B. et al. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pac. J. Cancer Prev. 15, 9611 (2014).
doi: 10.7314/APJCP.2014.15.22.9611
pubmed: 25520076
Yao, Y. et al. East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: An updated meta-analysis. Cancer Med. 13, e7080 (2024).
doi: 10.1002/cam4.7080
pubmed: 38457254
pmcid: 10923033
Luna, J. M. et al. Radiomic phenotypes for improving early prediction of survival in stage III non-small cell lung cancer adenocarcinoma after chemoradiation. Cancers 14, 700 (2022).
doi: 10.3390/cancers14030700
pubmed: 35158971
pmcid: 8833400
Tankyevych, O. et al. Development of radiomic-based model to predict clinical outcomes in non-small cell lung cancer patients treated with immunotherapy. Cancers 14, 5931 (2022).
doi: 10.3390/cancers14235931
pubmed: 36497415
pmcid: 9739232
Dissaux, G. et al. Pretreatment (18)F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: A multicentric study. J. Nucl. Med. 61, 814 (2020).
doi: 10.2967/jnumed.119.228106
pubmed: 31732678
Mu, W. et al. Radiomics of (18)F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur. J. Nucl. Med. Mol. Imaging 47, 1168 (2020).
doi: 10.1007/s00259-019-04625-9
pubmed: 31807885
Hannequin, P. et al. FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer. Transl. Lung Cancer Res. 11, 2051 (2022).
doi: 10.21037/tlcr-22-158
pubmed: 36386457
pmcid: 9641045
Huang, J. et al. CT-based radiomics helps to predict residual lung lesions in COVID-19 patients at three months after discharge. Diagnostics 11, 1814 (2021).
doi: 10.3390/diagnostics11101814
pubmed: 34679512
pmcid: 8534736
Pasini, G. et al. A critical analysis of the robustness of radiomics to variations in segmentation methods in (18)F-PSMA-1007 PET images of patients affected by prostate cancer. Diagnostics 13, 3640 (2023).
doi: 10.3390/diagnostics13243640
pubmed: 38132224
pmcid: 10743045
Pasini, G. et al. Phenotyping the histopathological subtypes of non-small-cell lung carcinoma: How beneficial is radiomics?. Diagnostics 13, 1167 (2023).
doi: 10.3390/diagnostics13061167
pubmed: 36980475
pmcid: 10046953